SteadyMed Ltd. (NASDAQ: STDY) Investor Investigation Over Takeover Announced

Investors who purchased shares of SteadyMed Ltd. (NASDAQ: STDY) and currently hold any of those NASDAQ: STDY shares have certain options and should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Steadymed
Affected Securities: 
NASDAQ: STDY

An investigation on behalf of investors, who currently hold shares of SteadyMed Ltd. (NASDAQ: STDY), was announced concerning whether the takeover of SteadyMed Ltd. is unfair to NASDAQ: STDY stockholders.

The investigation by a law firm concerns whether certain officers and directors of SteadyMed Ltd. breached their fiduciary duties owed to NASDAQ: STDY investors in connection with the proposed acquisition.

On April 30, 2018, United Therapeutics Corporation (NASDAQ:UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced the signing of a merger agreement under which United Therapeutics will acquire SteadyMed Ltd. (NASDAQ: STDY) for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®.

However, given that at least one analyst has set the high target price for NASDAQ:STDY shares at $15.00 per share, the investigation concerns whether the offer is unfair to SteadyMed Ltd. (NASDAQ: STDY stockholders.

In addition, given that certain SteadyMed Ltd. (NASDAQ: STDY) shareholders owning approximately 43.3 percent of the ordinary shares of SteadyMed have already entered into an agreement to vote their shares in favor of the transaction, the investigation concerns whether the SteadyMed Ltd. (NASDAQ: STDY Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.